- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 279/02 - 1,2-Thiazines; Hydrogenated 1,2-thiazines
Patent holdings for IPC class C07D 279/02
Total number of patents in this class: 84
10-year publication summary
|
10
|
4
|
7
|
6
|
2
|
8
|
2
|
11
|
2
|
1
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| F. Hoffmann-La Roche AG | 7958 |
7 |
| Genentech, Inc. | 3742 |
6 |
| Amgen Inc. | 3779 |
4 |
| Mochida Pharmaceutical Co., Ltd. | 334 |
4 |
| Merck Patent GmbH | 5909 |
3 |
| Resverlogix Corp. | 64 |
3 |
| Sunshine Lake Pharma Co., Ltd. | 542 |
3 |
| Vandria SA | 8 |
3 |
| Glaxo Group Limited | 4496 |
2 |
| Bristol-myers Squibb Company | 5080 |
2 |
| Janssen Pharmaceutica N.V. | 3839 |
2 |
| Riken | 1669 |
2 |
| Universita Degli Studi di Perugia | 39 |
2 |
| Universita degli Studi di Trento | 61 |
2 |
| Novartis AG | 11238 |
1 |
| Samsung Display Co., Ltd. | 30585 |
1 |
| Merck & Co., Inc. | 607 |
1 |
| Boehringer Ingelheim International GmbH | 4629 |
1 |
| Boehringer Ingelheim Pharma GmbH & Co. Kg | 790 |
1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 122 |
1 |
| Other owners | 33 |